MAY 29, 2014 07:30 AM PDT
Identification of predictive biomarkers from high throughput drug combination screening data
Presented at the Clinical Diagnostics and Research Virtual Event
20 46 1111

Speakers:
  • Director, Translational Medicine, Thermo-Fisher Scientific
    Biography
      With Thermo Fisher Scientific, Dr. Bowden leads Pharma Client Services to provide custom bioinformatics solutions for oncology drug development and research. This group develops complete solutions from target discovery and validation, predictive biomarkers of response and drug combination synergies, to clinical testing hypotheses   Dr. Bowden has more than 18 years of research and leadership experience in cancer biology and drug development in both academic and industry settings. She has served as an Assistant Professor at Georgetown University. While in industry, Dr. Bowden led multiple preclinical projects and strategy area teams supporting the development of various types of biologic including antibodies, multispecifics and antibody-drug conjugates. She holds a PhD in Biochemistry from University of Bristol. 

    Abstract:
    One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding and overcoming tumor heterogeneity as well as inherent or emerging resistance are areas of significant ongoing research in both clinical and preclinical settings. Systematic approaches to support combination therapy clinical trial design are critical. Zalicus Inc. and Life Technologies have collaborated to develop a joint service offering that supports rationale design of cell line panels to inform and address the relevant genomic aberrations in disease subsequently enabling the identification of (1) potentially synergistic therapy combinations, (2) biomarkers of synergy, and (3) identification of potential clinical populations for hypothesis testing. During this segment, Dr. Bowden will discuss technical aspects of combination screening and biomarker discovery, major considerations required for success, provide examples of results, and offer potential impacts of this innovative service offering.

    Show Resources
    Loading Comments...